Small-cell lung cancer (SCLC) is a disease characterised by inactivation of Rb1 and Tp53 tumour suppressor genes and activation of MYC and/or SOX2 oncogenes thus supporting cell proliferation [1, 2]. This evidence concerns the gene SOX2 and small cell lung carcinoma.